Patents Assigned to Shanghai Junshi Biosciences Co., Ltd.
-
Publication number: 20240117043Abstract: The present disclosure provides a bispecific antibody including a binding domain that binds to CD112R and a binding domain that binds to TIGIT, and the binding domain that binds to CD112R includes: HCDR1, HCDR2 and HCDR3 of the amino acid sequence set forth in SEQ ID NO: 1, and/or LCDR1, LCDR2 and LCDR3 of the amino acid sequence set forth in SEQ ID NO: 2; and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system. The present disclosure further provides a polynucleotide encoding the antibody, an expression vector, a host cell and a method for expressing and purifying the antibody, a pharmaceutical composition including the antibody of the present disclosure, and use of the bispecific antibody for treating cancer.Type: ApplicationFiled: August 4, 2023Publication date: April 11, 2024Applicants: SHANGHAI JUNSHI BIOSCIENCES CO., LTD., SUZHOU JUNMENG BIOSCIENCES CO., LTD.Inventors: Dandan LIU, Jinwei ZHOU, Yuehua ZHOU, Jing ZHANG, Sheng YAO, Hui FENG, Hui LIU, Hongchuan LIU, Li LI, Qiang ZHAO
-
Publication number: 20240067720Abstract: A stable anti-TIGIT antibody pharmaceutical composition and an application thereof. The pharmaceutical composition includes a buffer solution, and an anti-TIGIT antibody or an antigen-binding fragment thereof. The anti-TIGIT antibody or the antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3 having amino acid sequences as respectively represented by SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and LCDR1, LCDR2, and LCDR3 having amino acid sequences as respectively represented by SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. The pH of the pharmaceutical composition is about 5.0-6.5.Type: ApplicationFiled: January 14, 2022Publication date: February 29, 2024Applicants: SHANGHAI JUNSHI BIOSCIENCES CO., LTD., SUZHOU JUNMENG BIOSCIENCES CO., LTD.Inventors: Peixiang LIU, Hongchuan LIU, Jing ZHANG, Qiang ZHAO, Hui FENG
-
Publication number: 20230322929Abstract: The present disclosure relates to the use of an anti-BTLA antagonist (including antibodies and antigen binding fragments) in the treatment of various tumors, either as a mono therapy or a combination therapy with other immune checkpoint inhibitor therapy such as anti-PD-1 or anti-PD-L1, and methods of selecting subjects in need of treatment. Preferably, various solid tumors are treated.Type: ApplicationFiled: April 10, 2023Publication date: October 12, 2023Applicant: SHANGHAI JUNSHI BIOSCIENCES CO., LTD.Inventors: Sheng YAO, Hui FENG
-
Publication number: 20220363754Abstract: Provided are antibodies that bind specifically to TIGIT or antigen binding fragments of the antibodies and a composition thereof. Also provided are a nucleic acid molecule coding the antibodies or the antigen binding fragments thereof, an expression vector and a host cell for expressing the antibodies or the antigen binding fragments thereof, and therapeutic and diagnostic uses of the antibodies.Type: ApplicationFiled: July 14, 2020Publication date: November 17, 2022Applicants: SHANGHAI JUNSHI BIOSCIENCES CO., LTD., SUZHOU JUNMENG BIOSCIENCES CO., LTD.Inventors: Qin MENG, Jian YAO, Hui FENG, Sheng YAO, Hai WU
-
Patent number: 11225497Abstract: There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers.Type: GrantFiled: April 23, 2020Date of Patent: January 18, 2022Assignees: RISEN (SUZHOU) PHARMA TECH CO., LTD., SHANGHAI JUNSHI BIOSCIENCES CO., LTD.Inventors: Jiasheng Lu, Jiamin Gu, Gang Chen, Xiaolin Zhang, Feng Zhou, Xianqi Kong
-
Patent number: 10815302Abstract: This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprising cancers, infectious diseases and inflammatory diseases) by using the antibodies or the functional fragments thereof disclosed herein.Type: GrantFiled: July 25, 2018Date of Patent: October 27, 2020Assignees: Shanghai Junshi Biosciences Co., Ltd., Junmeng Biosciences Co., Ltd.Inventors: Bo Chen, Hai Wu, Hui Feng
-
Patent number: 9828423Abstract: The present invention belongs to the field of biopharmaceutics. Disclosed is an anti-BLyS antibody. The anti-BLyS antibody specifically targets BLyS, can combine with a B lymphocyte stimulating factor, and can inhibit the combination of the B lymphocyte stimulating factor with the receptor BR3-Fc thereof. Also provided are uses of the anti-BLyS antibody in the manufacture of a medicament for preventing and/or treating diseases caused by the excessive proliferation of B cells such as systemic lupus erythematorsus.Type: GrantFiled: May 22, 2013Date of Patent: November 28, 2017Assignees: WUHAN THERASOURCE BIOSCIENCES INC., SHANGHAI JUNSHI BIOSCIENCE CO., LTD.Inventors: Bo Chen, Hui Feng, Hongbing Shu